Literature DB >> 26768565

A US Food and Drug Administration perspective on evaluating medical products for Ebola.

Estelle Russek-Cohen1, Daniel Rubin2, Dionne Price2, Wellington Sun3, Edward Cox2, Luciana Borio4.   

Abstract

Entities:  

Keywords:  Ebola; Therapeutic clinical trials; vaccine clinical trials

Mesh：

Substances：

Year:  2016        PMID： 26768565     DOI： 10.1177/1740774515620613

Source DB:  PubMed          Journal:  Clin Trials        ISSN： 1740-7745            Impact factor:   2.486


× No keyword cloud information.
  3 in total

1.  First vaccine approval under the FDA Animal Rule.

Authors:  David W C Beasley; Trevor L Brasel; Jason E Comer
Journal:  NPJ Vaccines       Date:  2016-08-25       Impact factor: 7.344

2.  The public health value of vaccines beyond efficacy: methods, measures and outcomes.

Authors:  A Wilder-Smith; I Longini; P L Zuber; T Bärnighausen; W J Edmunds; N Dean; V Masserey Spicher; M R Benissa; B D Gessner
Journal:  BMC Med       Date:  2017-07-26       Impact factor: 8.775

Review 3.  The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges.

Authors:  Jonaid Ahmad Malik; Sakeel Ahmed; Aroosa Mir; Mrunal Shinde; Onur Bender; Farhan Alshammari; Mukhtar Ansari; Sirajudheen Anwar
Journal:  J Infect Public Health       Date:  2022-01-05       Impact factor: 3.718
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.